Abstract
The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cytokines / blood
-
Disability Evaluation
-
Dose-Response Relationship, Drug
-
Fatigue / chemically induced
-
Female
-
Guillain-Barre Syndrome / drug therapy*
-
Guillain-Barre Syndrome / immunology
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Interferon beta-1a
-
Interferon-beta / adverse effects
-
Interferon-beta / therapeutic use*
-
Lymphopenia / chemically induced
-
Male
-
Middle Aged
-
Pilot Projects
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use*
-
Treatment Outcome
Substances
-
Cytokines
-
Immunoglobulins, Intravenous
-
Recombinant Proteins
-
Interferon-beta
-
Interferon beta-1a